Longevity & AgingResearch PaperOpen Access

Higher Blood Ergothioneine Levels Linked to 40% Lower Dementia Risk in Japanese Study

11-year study of 1,344 older adults shows mushroom-derived antioxidant ergothioneine may protect against Alzheimer's and other dementias.

Sunday, April 26, 2026 3 views
Published in Psychiatry Clin Neurosci
Vibrant assortment of fresh mushrooms (shiitake, oyster, button) arranged on wooden cutting board with elderly hands reaching for them in warm kitchen lighting

Summary

A landmark 11-year study of 1,344 Japanese adults aged 65+ found that higher blood levels of ergothioneine—a powerful antioxidant found primarily in mushrooms—were associated with significantly lower dementia risk. Participants in the highest quartile of serum ergothioneine had approximately 40% lower risk of developing all-cause dementia, Alzheimer's disease, and non-Alzheimer's dementias compared to those in the lowest quartile. Since humans cannot produce ergothioneine, these findings suggest that consuming ergothioneine-rich foods, particularly mushrooms, may offer meaningful protection against cognitive decline and dementia in aging populations.

Deep Dive Audio
0:00--:--

Detailed Summary

This groundbreaking prospective study from the renowned Hisayama Study provides compelling evidence that ergothioneine, a unique antioxidant compound found predominantly in mushrooms, may significantly reduce dementia risk in older adults. The research matters because it's the first large-scale, long-term population study to demonstrate this protective association using objective biomarker measurements rather than dietary questionnaires.

Researchers followed 1,344 Japanese community residents aged 65 and older for a median of 11.2 years (2012-2023), measuring baseline serum ergothioneine levels using advanced liquid chromatography-mass spectrometry. Participants were divided into quartiles based on their ergothioneine concentrations and monitored for dementia development through comprehensive neuropsychological evaluations and clinical assessments.

The results were striking: 273 participants developed dementia during follow-up (201 with Alzheimer's disease, 72 with non-Alzheimer's dementia). Those in the highest ergothioneine quartile showed dramatically lower risk across all dementia types. The protective effect remained robust even after adjusting for cardiovascular factors, lifestyle variables, and importantly, daily vegetable intake—suggesting ergothioneine's benefits extend beyond general healthy eating patterns.

Subgroup analyses revealed that ergothioneine's protective effects were consistent regardless of participants' vegetable consumption levels, indicating this compound offers unique neuroprotective benefits. Since ergothioneine cannot be synthesized by the human body and blood levels reflect dietary intake over approximately one month, these findings directly support the potential for dietary interventions.

The implications are significant for aging populations worldwide. Mushrooms represent the richest dietary source of ergothioneine, with some varieties containing exceptionally high concentrations. This research provides scientific backing for incorporating mushroom consumption into dementia prevention strategies, offering a practical, accessible intervention that could complement existing recommendations for brain health.

Key Findings

  • Highest ergothioneine quartile associated with ~40% lower all-cause dementia risk
  • Protective effects observed for both Alzheimer's and non-Alzheimer's dementias
  • Benefits remained significant after adjusting for vegetable intake and lifestyle factors
  • Ergothioneine protection consistent across different dietary patterns
  • First large-scale prospective study linking blood ergothioneine to dementia prevention

Methodology

Prospective cohort study of 1,344 Japanese adults aged 65+ followed for median 11.2 years. Serum ergothioneine measured via liquid chromatography-mass spectrometry at baseline, with comprehensive dementia assessments throughout follow-up using established clinical criteria.

Study Limitations

Single-ethnicity population may limit generalizability to other groups. Observational design cannot establish causation. Ergothioneine measured only at baseline, not accounting for changes over time. Residual confounding from unmeasured lifestyle or genetic factors possible.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.